Adaptimmune Therapeutics PLC (ADAP)
1.105
-0.02
(-2.21%)
USD |
NASDAQ |
May 07, 09:58
Adaptimmune Therapeutics Cash from Financing (TTM): 0.88M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.88M |
September 30, 2023 | 2.209M |
June 30, 2023 | 3.065M |
March 31, 2023 | 13.03M |
December 31, 2022 | 12.87M |
September 30, 2022 | 11.52M |
June 30, 2022 | 10.20M |
March 31, 2022 | 2.789M |
December 31, 2021 | 3.288M |
September 30, 2021 | 3.358M |
June 30, 2021 | 3.685M |
March 31, 2021 | 249.14M |
December 31, 2020 | 340.05M |
September 30, 2020 | 339.93M |
June 30, 2020 | 339.46M |
March 31, 2020 | 91.77M |
Date | Value |
---|---|
December 31, 2019 | 0.366M |
September 30, 2019 | 0.47M |
June 30, 2019 | 100.63M |
March 31, 2019 | 101.19M |
December 31, 2018 | 102.69M |
September 30, 2018 | 102.59M |
June 30, 2018 | 2.794M |
March 31, 2018 | 43.70M |
December 31, 2017 | 103.57M |
September 30, 2017 | 103.58M |
June 30, 2017 | 103.22M |
March 31, 2017 | 61.41M |
December 31, 2016 | 0.017M |
September 30, 2016 | 0.00 |
June 30, 2016 | -4.093M |
March 31, 2016 | 94.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.366M
Minimum
Dec 2019
340.05M
Maximum
Dec 2020
80.46M
Average
10.20M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Biodexa Pharmaceuticals Plc | 12.76M |
NuCana PLC | -0.0659M |
Autolus Therapeutics PLC | -0.883M |
TC BioPharm (Holdings) PLC | 10.62M |
Bicycle Therapeutics PLC | 249.18M |